Piglet saphenous vein contains multiple relaxatory prostanoid receptors: Evidence for EP 4, EP 2, DP and IP receptor subtypes

British Journal of Pharmacology

Volumn 144, Issue 3, 2005, Pages 405-415

  Wilson, Richard J ^a   Giles, Heather ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

DP; EP 4; EP 2; EP 4 antagonist; GW627368X; IP; Prostanoid; Receptor; Saphenous; Venous pharmacology

Indexed keywords

(4 BENZOYLAMINO)PHENYL 7 [(3 HYDROXY 3 PHENOXYPROPOXY) 5 OXOCYCLOPENTYL] 4 HEPTENOATE; 11 DEOXYPROSTAGLANDIN E1; 16,16 DIMETHYLPROSTAGLANDIN E2; 17 PHENYL OMEGA TRINORPROSTAGLANDIN E2; 19 HYDROXYPROSTAGLANDIN E2; 3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; BENZENE DERIVATIVE; BUTAPROST; CICAPROST; CLOPROSTENOL; FLUPROSTENOL; GR 637799X; GW 627368X; ILOPROST; MISOPROSTOL; N [2 [4 (4,9 DIETHOXYL 1 OXO 1,3 DIHYDRO 2H BENZ[F]ISOINDOL 2 YL)PHENYL]ACETYL]BENZENESULFONAMIDE; PHENYLEPHRINE; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTANOID RECEPTOR; RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; RECOMBINANT RECEPTOR; SEROTONIN; SULPROSTONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ANTAGONISM; DRUG POTENCY; ENDOTHELIUM; FEMALE; HUMAN; HUMAN CELL; KIDNEY CELL; MALE; NONHUMAN; PRIORITY JOURNAL; SAPHENOUS VEIN; SWINE;

ACETYLCHOLINE; ALGORITHMS; ANIMALS; DINOPROSTONE; FEMALE; HUMANS; ILOPROST; ISOMETRIC CONTRACTION; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E; SAPHENOUS VEIN; SWINE; VASODILATOR AGENTS;

EID: 14644417862     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706088     Document Type: Article

References (35)

1. ABRAMOWITZ, M., ADAM, M., BOIE, Y., CARRIERE, D.D., GODBOUT, C., LAMONTAGNE, S., ROCHETTE, C., SAWYER, N., TREMBLAY, N.M., BELLEY, M., GALLANT, M., DUFRESNE, C., GAREAU, Y., RUEL, R., JUTEAU, H., LABELLE, M., OUIMET, N. & METTERS, K. (2000). The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta, 1483, 285-293.
2. ANGELINI, G.D., BRYAN, A.J., WILLIAMS, H.M., MORGAN, R. & NEWBY, A.C. (1990). Distention promotes platelet and leukocyte adhesion and reduces short-term patency in pig arteriovenous bypass grafts. J. Thor. Cardiovasc. Surg., 99, 433-439.
3. 3 receptors. Adv. Prost. Thromb. Leuk. Res., 21, 379-382.
4. COLEMAN, R.A., GRIX, S.P., HEAD, S.A., LOUTIT, J.B., MALLETT, A. & SHELDRICK, R.L.G. (1994a). A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins, 47, 151-168.
5. COLEMAN, R.A., SMITH, W.L. & NARUMIYA, S. (1994b). International Union of Pharmacology VIII. Classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmacol. Rev., 46, 205-229.
6. 4 antagonists - useful for the treatment of e.g. rheumatoid arthritis, osteoarthritis, gouty arthritis, myositis or rheumatic fever (WO200250032-A1).
7. 4 receptor antagonist. Poster at the 224th ACS National Meeting, August 18-22, 2002, Boston, Abstract MEDI-306.
8. 2. Prostaglandins, 35, 277-300.
9. GILES, H., LEFF, P., BOLOFO, M.L., KELLY, M.G. & ROBERTSON, A.D. (1989). The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br. J. Pharmacol., 96, 291-300.
10. 2 selectively induces chemotaxis in T-helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med., 193, 225-261.
11. HUMBLES, A.A., NIALS, A.T. & COLEMAN, R.A. (1991). Pharmacological characterisation of the prostanoid receptors in the rabbit isolated ear artery. Br. J. Pharmacol., 104, 418.
12. 1 systems in blood vessels of piglets. Br. J. Pharmacol., 131, 63.
13. 3-receptor in guinea-pig aorta - partial agonist action of the non-prostanoid ONO-AP-324. Br. J. Pharmacol., 125, 1288-1296.
14. JONES, R.L., QIAN, Y.-M., WONG, H.N.C., CHAN, H.W. & YIM, A.P.C. (1997). Prostanoid action on the human pulmonary vascular system. Clin. Exp. Pharmacol. Phys., 24, 969-972.
15. KENAKIN, T. (1993). Methods of drug and receptor classification. In: Pharmacologic Analysis of Drug-Receptor Interaction. pp. 344-384. New York: Raven.
16. KENAKIN, T. (2002). Drug efficacy at G protein coupled receptors. Ann. Rev. Pharmacol. Toxicol., 42, 349-379.
17. KIRIYAMA, M., USHIKUBI, F., KOBAYASHI, T., HIRATA, M., SUGIMOTO, Y. & NARUMIYA, S. (1997). Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol., 122, 217-224.
18. LEW, M.J. & ANGUS, J.A. (1995). Analysis of competitive agonist-antagonist interactions by non-linear regression. Trends Pharmacol. Sci., 16, 328-337.
19. LI, R.-C, CINDROVA-DAVIES, T., SKEPPER, J.N. & SELLERS, L.A. (2004). Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor. Circ. Res., 94, 759-767.
20. LIU, Y.J., JACKSON, D.M. & BLACKHAM, A. (1996). Effects of BW A868C, a selective prostaglandin DP receptor antagonist in dog isolated vascular preparations. Eur. J. Pharmacol., 303, 187-192.
21. 2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br. J. Pharmacol., 97, 783-794.
22. LYDFORD, S.J., MCKECHNIE, K.C.W. & DOUGALL, I.G. (1996a). Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. Br. J. Pharmacol., 117, 13-20.
23. LYDFORD, S.J., MCKECHNIE, K.C.W. & LEFF, P. (1996b). Interaction of BW A868C, a prostanoid DP-receptor antagonist, with two receptor subtypes in the rabbit isoltaed saphenous vein. Prostaglandins, 52, 125-139.
24. MACLENNAN, S.J., BOLOFO, M.L. & MARTIN, G.R. (1993). Amplifying interactions between spasmogens in vascular smooth muscle. Biochem. Soc. Trans., 21, 1145-1150.
25. MILNE, S.A., ARMSTRONG, R.A. & WOODWARD, D.F. (1995). Comparison of the EP receptor subtypes mediating relaxation of the rabbit jugular and pig saphenous veins. Prostaglandins, 49, 225-237.
26. NARUMIYA, S., SUGIMOTO, Y. & USHIKUBI, F. (1999). Prostanoid receptors: structures, properties and functions. Phys. Rev., 79, 1193-1226.
27. 3-receptor agonists on human isolated pulmonary artery. Br. J. Pharmacol., 113, 369-374.
28. 2-receptors and molecular mechanisms in platelets and vasculature: state of the art. Pharm. Res. Commun., 19, 735-765.
29. 2-mediated relaxation. Br. J. Pharmacol., 126, 35-44.
30. 1 and IP-receptor agonist. Br. J. Pharmacol., 94, 334.
31. 2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation. Circulation, 62, V19-V25.
32. 1- and TP-receptors involved in the contraction of human pulmonary veins. Br. J. Pharmacol., 134, 1671-1678.
33. WHITTLE, B.J.R., MONCADA, S., MULLANE, K. & VANE, J.R. (1983). Platelet and cardiovascular activity of the hydantoin BW 245C, a potent prostaglandin analogue. Prostaglandins, 25, 205-223.
34. 4 prostanoid receptor antagonist. Br. J. Pharmacol., 138, 84.
35. 4 receptors. Eur. J. Pharmacol., 501, 49-58.